KF
SGMO

Kelsey Financial’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Kelsey Financial’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Buy
42,000
+7,000
+20% +$2.79K 0.01% 62
2025
Q4 		$14.7K Buy
+35,000
New +$18.6K 0.01% 61

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Kelsey Financial's SGMO Position: Q1 2026 in Review

Kelsey Financial increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 20% in Q1 2026, buying an estimated $2.79K and bringing the position to 42,000 shares worth $10.4K. The position accounts for 0.01% of the portfolio, ranked #62.

Kelsey Financial first reported a position in SGMO in Q4 2025 and has held it in 2 quarters since. The position peaked at $14.7K in Q4 2025. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Kelsey Financial held 42,000 shares of SANGAMO THERAPEUTICS INC worth $10.4K as of Q1 2026.
  • Kelsey Financial bought 7,000 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $2.79K.
  • SANGAMO THERAPEUTICS INC made up 0.01% of Kelsey Financial's portfolio in Q1 2026, its #62 holding.
  • Kelsey Financial first reported a position in SANGAMO THERAPEUTICS INC in Q4 2025 and has held it in 2 quarters since.
  • Kelsey Financial's SANGAMO THERAPEUTICS INC position peaked at $14.7K in Q4 2025.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Kelsey Financial's 13F filing for Q1 2026, filed 6 May 2026.